Howard joined Xalud Therapeutics with decades of relevant industry and healthcare experience. Prior to his role at Xalud, Dr. Rutman was vice president of medical affairs for Daiichi Sankyo’s US Business Division. In that role, he led the medical affairs group across all therapeutic areas to enhance the awareness of Daiichi Sankyo’s US approved- and clinical-stage products through the generation, interpretation and exchange of high quality medical and scientific information valued by internal and external stakeholders. Prior to joining Daiichi Sankyo, Howard was at Pfizer as the senior director and global medical affairs lead for multiple monoclonal antibody biosimilars under development in oncology and immunology. Dr. Rutman began his pharmaceutical career at Taro Pharmaceuticals as group vice president for medical affairs and clinical drug development. Before his roles in the industry, Howard practiced cardiology in a New York-based academic, private practice, with a focus on managing patients with chronic congestive heart failure.
Howard has a B.A. in biochemical sciences and molecular biology from Harvard College. He received his M.D. from Johns Hopkins University School of Medicine and holds an MBA from New York University. He completed his medical residency at New York-Presbyterian Hospital and his cardiology fellowship at Albert Einstein College of Medicine. He continues to serve on the teaching faculty of the Mount Sinai School of Medicine.
Howard has a B.A. in biochemical sciences and molecular biology from Harvard College. He received his M.D. from Johns Hopkins University School of Medicine and holds an MBA from New York University. He completed his medical residency at New York-Presbyterian Hospital and his cardiology fellowship at Albert Einstein College of Medicine. He continues to serve on the teaching faculty of the Mount Sinai School of Medicine.
Speaking In
4:15 PM - 5:15 PM
Tuesday, June 6
